Evaluation of recurrence in localized and metastatic prostate
cancer
For patients with localized prostate cancer, after radical
prostatectomy, two consecutive serum PSA values higher than 0.2 ng/mL
and/or increment were defined as biochemical recurrence (BCR).
Currently, BCR has been accepted as the first rise (≥0.2ng/mL) in
PSA25.
For patients with metastatic prostate cancer, castration resistance
prostate cancer (CRPC) accepted for recurrence. CRPC is defined as
castrating serum testosterone <50 ng/dl or 1.7 nmol/l plus one
of the following types of progression.
Biochemical progression: Three consecutive rises in PSA 1 week apart,
resulting in two 50% increases over the nadir, and PSA > 2
ng/ml.
Radiologic progression: The appearance of new lesions: either two or
more new bone lesions on bone scan or a soft tissue lesion using the
Response Evaluation Criteria in Solid Tumours
(RECIST)26,27.